Article

Adjusting Speed of Cancer Cell DNA Repair Vital to Overcome Chemotherapy Resistance

A specific mark in histones speeds up repairs in cancer cells, increasing their resistance to treatment.

By wrapping around cancer cell DNA and forming a protective shield, histones help speed up the repair process and increase chemotherapy resistance, according to a study published in Nucleic Acids Research.

A majority of chemotherapies and radiotherapies kill cancer cells by creating breaks in the DNA, but cancer cells are able to resist treatment by fixing the breaks.

“If we can find a way to hijack the cancer’s fix and repair toolkit and make it less efficient, then we can tip the scale in favor of cancer cell death instead of survival and prevent resistance to chemotherapy,” said lead researcher Sherif El-Khamisy.

Findings from a new study indicate that the key to preventing treatment resistance to a common class of chemotherapy used on breast and colon cancer patients is to change the speed that cancer cells repair the damage to their DNA.

“We have discovered that resistance to a common class of chemotherapy, used to treat colon and breast cancer, is caused by changes in the speed by which the tool kit components travel to, and stay at, the sites of DNA breaks,” El-Khamisy said. “Our researchers were able to identify a change in a specific mark in the proteins that wrap the DNA — called histones – in such a way that makes repair much faster in cancer cells, increasing their resistance to therapy. The change we identified is not genetic – but epigenetic.”

The findings indicate that patients who develop treatment resistance to certain classes of chemotherapy can benefit from drugs that modulate histone marks, such as histone deacetylase inhibitors.

“We only focused on a class of chemotherapy used to treat colon and breast cancer called topoisomerase 1 inhibitors,” El-Khamisy said. “It is possible that the same mechanism holds true for other classes of chemotherapy.”

Related Videos
Anthony Perissinotti, PharmD, BCOP, discusses unmet needs and trends in managing chronic lymphocytic leukemia (CLL), with an emphasis on the pivotal role pharmacists play in supporting medication adherence and treatment decisions.
Image Credit: © alenamozhjer - stock.adobe.com
pharmacogenetics testing, adverse drug events, personalized medicine, FDA collaboration, USP partnership, health equity, clinical decision support, laboratory challenges, study design, education, precision medicine, stakeholder perspectives, public comment, Texas Medical Center, DNA double helix
pharmacogenetics challenges, inter-organizational collaboration, dpyd genotype, NCCN guidelines, meta census platform, evidence submission, consensus statements, clinical implementation, pharmacotherapy improvement, collaborative research, pharmacist role, pharmacokinetics focus, clinical topics, genotype-guided therapy, critical thought
Image Credit: © Andrey Popov - stock.adobe.com
Image Credit: © peopleimages.com - stock.adobe.com
TRUST-I and TRUST-II Trials Show Promising Results for Taletrectinib in ROS1+ NSCLC
World Standards Week 2024: US Pharmacopeia’s Achievements and Future Focus in Pharmacy Standards